Feasibility of 10-Day Use of a Continuous Glucose Monitoring System in Adults with Type 1 Diabetes
- Satish K. Garg, MD (satish.garg{at}uchsc.edu)1,2,3,
- Mary K. Voelmle, FNP1 and
- Peter Gottlieb, MD1,2,3
- 1Barbara Davis Center for Childhood Diabetes,
- 2Departments of Internal Medicine, and
- 3Pediatrics, University of Colorado Denver, Aurora, Colorado
Abstract
Background the purpose of this pilot study was to evaluate feasibility of 10-day use of a transcutaneous, real-time, continuous glucose monitoring (cgm) system. All previous reports using different cgm systems were for 3, 5, or 7-day use.
Methods On Day1, subjects received the CGM device (SEVEN® System) and underwent training on proper use. Subjects returned to the clinic on Days2, 7 and 10 for in-clinic sessions. On Days2 and 7, half of the subjects performed fingersticks every 15minutes and the other half had YSI samples drawn every 15minutes. On Day10, subjects participated in an 8-hour in-clinic session with YSI and fingerstick testing.
Results The MARD for CGM vs. YSI was 12.6%, 11.3%, and 14.5% on Days2, 7, and 10, respectively (p=0.63). The CGM compared with SMBG performed better on Day10.
Conclusions This is the first study that documents usability for 10 days of a CGM system was stable.
Footnotes
-
- Received September 22, 2008.
- Accepted November 15, 2008.
- Copyright © American Diabetes Association
